See more : Permanent TSB Group Holdings plc (IL0A.IR) Income Statement Analysis – Financial Results
Complete financial analysis of ClearPoint Neuro, Inc. (CLPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ClearPoint Neuro, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Genesis Unicorn Capital Corp. (GENQU) Income Statement Analysis – Financial Results
- Seneca Growth Capital VCT plc (HYG.L) Income Statement Analysis – Financial Results
- Endo International plc (0Y5F.L) Income Statement Analysis – Financial Results
- BioHarvest Sciences Inc. Common Stock (BHST) Income Statement Analysis – Financial Results
- Poseidon Nickel Limited (PSDNF) Income Statement Analysis – Financial Results
ClearPoint Neuro, Inc. (CLPT)
About ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.96M | 20.55M | 16.30M | 12.83M | 11.22M | 7.35M | 7.38M | 5.75M | 4.59M | 3.60M | 3.93M | 5.06M | 3.82M | 2.67M |
| Cost of Revenue | 10.34M | 7.02M | 5.01M | 3.71M | 3.83M | 2.43M | 2.90M | 2.64M | 1.99M | 1.93M | 1.42M | 555.70K | 656.41K | 16.31K |
| Gross Profit | 13.61M | 13.53M | 11.29M | 9.12M | 7.38M | 4.92M | 4.48M | 3.11M | 2.61M | 1.68M | 2.51M | 4.50M | 3.16M | 2.65M |
| Gross Profit Ratio | 56.83% | 65.84% | 69.27% | 71.09% | 65.83% | 66.91% | 60.72% | 54.03% | 56.74% | 46.53% | 63.84% | 89.01% | 82.81% | 99.39% |
| Research & Development | 11.71M | 10.89M | 8.99M | 4.69M | 2.92M | 2.31M | 2.81M | 2.63M | 1.96M | 3.30M | 2.92M | 1.60M | 4.25M | 5.68M |
| General & Administrative | 11.76M | 9.61M | 8.76M | 5.27M | 4.30M | 4.33M | 4.05M | 4.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 12.60M | 9.36M | 6.92M | 5.38M | 4.76M | 3.53M | 3.96M | 3.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.35M | 18.97M | 15.68M | 10.65M | 9.06M | 7.86M | 8.00M | 7.97M | 8.37M | 8.04M | 7.06M | 6.03M | 4.83M | 4.70M |
| Other Expenses | 0.00 | -22.00K | -63.00K | 882.00K | 9.05K | 364.00 | 16.68K | 216.08K | 230.88K | 1.80M | 863.79K | 2.80K | 104.85K | 413.62K |
| Operating Expenses | 36.06M | 29.86M | 24.67M | 15.34M | 11.98M | 10.17M | 10.82M | 10.60M | 10.33M | 11.34M | 9.98M | 7.63M | 9.08M | 10.38M |
| Cost & Expenses | 46.40M | 36.88M | 29.67M | 19.05M | 15.81M | 12.60M | 13.72M | 13.24M | 12.32M | 13.26M | 11.41M | 8.19M | 9.74M | 10.40M |
| Interest Income | 386.00K | 81.00K | 973.00K | 1.44M | 955.00K | 0.00 | 0.00 | 8.81K | 16.46K | 11.62K | 24.54K | 14.15K | 3.48K | 10.40K |
| Interest Expense | 0.00 | 81.00K | 973.00K | 1.44M | 955.17K | 980.38K | 872.93K | 1.06M | 1.26M | 1.01M | 475.30K | 2.58M | 2.50M | 1.59M |
| Depreciation & Amortization | 1.46M | 777.00K | 692.00K | 550.00K | 250.56K | 109.44K | 116.45K | 155.71K | 211.95K | 377.26K | 426.18K | 416.97K | 354.89K | 266.22K |
| EBITDA | -20.99M | -15.58M | -12.75M | -4.79M | -4.33M | -5.07M | -6.18M | -6.85M | -6.97M | -3.13M | -6.16M | -2.70M | -5.46M | -7.60M |
| EBITDA Ratio | -87.62% | -75.80% | -78.19% | -37.30% | -38.64% | -69.87% | -84.05% | -123.63% | -158.07% | -217.95% | -168.19% | -61.81% | -145.70% | -279.09% |
| Operating Income | -22.45M | -16.33M | -13.37M | -6.22M | -4.59M | -5.25M | -6.34M | -7.49M | -8.97M | -5.32M | -7.47M | -3.13M | -5.92M | -9.52M |
| Operating Income Ratio | -93.70% | -79.47% | -82.05% | -48.48% | -40.95% | -71.37% | -85.86% | -130.25% | -195.34% | -147.61% | -190.17% | -61.87% | -155.09% | -356.45% |
| Total Other Income/Expenses | 357.00K | -103.00K | -1.04M | -562.00K | -945.79K | -915.70K | -831.52K | -581.16K | 524.86K | 795.89K | 388.50K | -2.58M | -2.39M | 61.06K |
| Income Before Tax | -22.09M | -16.44M | -14.41M | -6.78M | -5.54M | -6.16M | -7.17M | -8.07M | -8.45M | -4.52M | -7.09M | -5.71M | -8.31M | -9.45M |
| Income Before Tax Ratio | -92.21% | -79.97% | -88.41% | -52.86% | -49.39% | -83.82% | -97.12% | -140.36% | -183.91% | -125.53% | -180.29% | -112.83% | -217.68% | -354.16% |
| Income Tax Expense | 0.00 | 103.00K | 910.00K | 2.33M | 964.22K | 64.68K | 889.61K | 1.28M | 1.49M | 2.43M | 912.90K | 2.17M | 2.50M | 1.59M |
| Net Income | -22.09M | -16.54M | -15.32M | -9.11M | -6.50M | -6.16M | -7.17M | -8.07M | -8.45M | -4.52M | -7.09M | -5.71M | -8.31M | -9.45M |
| Net Income Ratio | -92.21% | -80.47% | -93.99% | -71.00% | -57.98% | -83.82% | -97.12% | -140.36% | -183.91% | -125.53% | -180.29% | -112.83% | -217.68% | -354.16% |
| EPS | -0.90 | -0.68 | -0.74 | -0.57 | -0.49 | -0.56 | -0.93 | -2.93 | -4.48 | -3.06 | -4.95 | -5.65 | -20.73 | -23.76 |
| EPS Diluted | -0.90 | -0.68 | -0.74 | -0.57 | -0.49 | -0.56 | -0.93 | -2.93 | -4.48 | -3.06 | -4.95 | -5.65 | -20.73 | -23.76 |
| Weighted Avg Shares Out | 24.61M | 24.18M | 20.73M | 15.85M | 13.16M | 10.93M | 7.74M | 2.75M | 1.88M | 1.48M | 1.43M | 1.01M | 401.03K | 397.98K |
| Weighted Avg Shares Out (Dil) | 24.61M | 24.18M | 20.73M | 15.85M | 13.16M | 10.93M | 7.74M | 2.75M | 1.88M | 1.48M | 1.43M | 1.01M | 401.03K | 397.98K |
Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons
Aspen Neuroscience Announces MRI-Guided Transplantation Approach for ASPIRO Clinical Trial with the ClearPoint® Navigation System SAN DIEGO , June 20, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc. announced today that it is utilizing the MRI-guided ClearPoint® Navigation System for all patients enrolled...
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announces full market release of its SmartFrame...
Does ClearPoint Neuro (CLPT) Have the Potential to Rally 81.49% as Wall Street Analysts Expect?
The consensus price target hints at an 81.5% upside potential for ClearPoint Neuro (CLPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know
The mean of analysts' price targets for ClearPoint Neuro (CLPT) points to a 70.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
ClearPoint Neuro, Inc. (CLPT) Q1 2024 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Joe Burnett – Chief Executive Officer Danilo D'Alessandro – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
NEW YORK , May 2, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ClearPoint Neuro, Inc. (NASDAQ: CLPT) on behalf of the company's shareholders. The investigation seeks to determine whether ClearPoint Neuro's directors breached their fiduciary...
7 Penny Stocks That Could Make You a Fortune (If You Dare)
Penny stocks are on the riskier end of the public equity spectrum. They are characterized by their low volume, affordable pricing, and the rapid pace at which their values can surge or plummet compared to more traditional stocks.
ClearPoint Neuro: Macro-Induced Multiple Compression
ClearPoint Neuro: Macro-Induced Multiple Compression
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
ClearPoint Neuro platform and SmartFlow Cannula to be used by all centers in AviadoBio's ASPIRE-FTD gene therapy trial treating frontotemporal dementia
Source: https://incomestatements.info
Category: Stock Reports